Subscribe to RSS
DOI: 10.1055/a-0863-4692
Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines?
![](https://www.thieme-connect.de/media/pharmaco/202004/lookinside/thumbnails/2018-11-0791_10-1055-a-0863-4692-1.jpg)
Abstract
Introduction Expert groups have created dosing guidelines to facilitate the implementation of pharmacogenetic knowledge into clinical practice and commercial pharmacogenetic tests are becoming increasingly accessible. However, the extent to which these commercial tests facilitate the implementation of dosing guidelines is not clear.
Methods Gene-drug pairs included on 22 commercial pharmacogenetic test panels were extracted and cross-referenced with the 74 gene-drug pairs with dosing guidelines in the Pharmacogenetics Knowledgebase, with particular attention given to the 28 gene-drug pairs relevant to psychiatry.
Results On average, 70% of the 28 gene-drug pairs most relevant to psychiatry were covered by the examined tests. Six gene-drug pairs (CYP2D6-venlafaxine, CYP2D6-paroxetine, CYP2D6-amitriptyline, CYP2C19-sertraline, CYP2C19-citalopram, CYP2C19-amitriptyline) were included by all tests. Gene-drug pairs included on less than half of the test panels included HLA-B-phenytoin (14%), HLA-A-carbamazepine (24%), HLA-B-carbamazepine (29%), and CYP2D6-zuclopenthixol (43%).
Discussion Most commercial pharmacogenetic tests we examined are well-equipped to facilitate implementation of the majority of dosing guidelines relevant to psychiatry but are limited in their ability to facilitate implementation of the full spectrum of dosing guidelines currently available.
Publication History
Received: 07 November 2018
Received: 07 February 2019
Accepted: 15 February 2019
Article published online:
21 March 2019
© Georg Thieme Verlag KG
Stuttgart · New York
-
References
- 1 Swen JJ, Nijenhuis M, de Boer A. et al. Pharmacogenetics: From bench to byte–an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-673
- 2 Relling MV, Klein TE. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011; 89: 464-467
- 3 Ross CJ, Visscher H, Sistonen J. et al. The Canadian Pharmacogenomics Network for Drug Safety: A model for safety pharmacology. Thyroid 2010; 20: 681-687
- 4 Haga SB, Kantor A. Horizon scan of clinical laboratories offering pharmacogenetic testing. Health Aff 2018; 37: 717-723
- 5 Bousman CA, Jaksa P, Pantelis C. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: A focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Pharmacogenet Genomics 2017; 27: 387-393
- 6 Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 2016; 3: 585-590
- 7 Whirl-Carrillo M, McDonagh EM, Hebert JM. et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92: 414-417
- 8 Aminkeng F, Ross CJ, Rassekh SR. et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol 2016; 82: 683-695
- 9 Clancy JP, Johnson SG, Yee SW. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther 2014; 95: 592-597
- 10 Relling MV, McDonagh EM, Chang T. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther 2014; 96: 169-174
- 11 Hicks JK, Sangkuhl K, Swen JJ. et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2016; 102: 37-44
- 12 Hicks JK, Bishop JR, Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98: 127-134
- 13 Bousman C, Dunlop B. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J 2018; 18: 613-622
- 14 Duong TA, Valeyrie-Allanore L, Wolkenstein P. et al. Severe cutaneous adverse reactions to drugs. Lancet 2017; 390: 1996-2011